Market Access News | pharmaphorum

News

Bristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.

News

Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.

News

ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.

News

Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.

News

Trump has signed an order that rips up the current US policy on childhood vaccines, demanding changes that experts say will put children at risk.

News

Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.